{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:29:42Z","timestamp":1780464582841,"version":"3.54.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Stake Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund","award":["SKL-HIDCA-2021-BF2"],"award-info":[{"award-number":["SKL-HIDCA-2021-BF2"]}]},{"name":"Scientific Research Project of the Eighth Affiliated Hospital of Xinjiang Medical University","award":["2023014"],"award-info":[{"award-number":["2023014"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Drug therapy is the most effective therapy for tuberculosis; however, it can also lead to a common and serious adverse reaction known as antituberculosis drug\u2013induced liver injury. The incidence of antituberculosis drug\u2013induced liver injury ranges from 2.0% to 28.0%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>Here, we report the successful treatment of drug-induced fulminant hepatitis in a 19-year-old patient with extensively drug-resistant tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient was treated with a combination of bedaquiline, linezolid, cycloserine, clofazimine, amikacin, ethambutol, and pyrazinamide. This combination was selected because the patient showed resistance to rifampicin, isoniazid, and fluoroquinolones in a drug resistance test. However, for personal reasons, the patient did not follow the doctor\u2019s advice and developed fulminant hepatitis induced by antituberculosis drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Antituberculosis drugs were immediately discontinued, and the patient received clinical treatment for liver protection, jaundice elimination, artificial liver support, and infusion of fibrinogen and prothrombin complex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Gradually, the patient\u2019s liver function returned to normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case report highlights the importance of regular liver function monitoring during antituberculosis therapy to ensure patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045893","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:00:59Z","timestamp":1764169259000},"page":"e45893","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Fulminant hepatitis during treatment for per-extensively drug-resistant tuberculosis: A case report and call for improved patient monitoring"],"prefix":"10.1097","volume":"104","author":[{"given":"Tian","family":"Zheng","sequence":"first","affiliation":[{"name":"The First Department of Tuberculosis, The Sixth People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aierkenjiang","family":"Malipati","sequence":"additional","affiliation":[{"name":"The First Department of Tuberculosis, The Sixth People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Guo","sequence":"additional","affiliation":[{"name":"The First Department of Tuberculosis, The Sixth People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Guan","sequence":"additional","affiliation":[{"name":"The First Department of Tuberculosis, The Sixth People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Yang","sequence":"additional","affiliation":[{"name":"The First Department of Tuberculosis, The Sixth People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"An","sequence":"additional","affiliation":[{"name":"The First Department of Tuberculosis, The Sixth People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abuduwaili","family":"Rouzihan","sequence":"additional","affiliation":[{"name":"The First Department of Tuberculosis, The Sixth People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5325-977X","authenticated-orcid":false,"given":"Abudushalamu","family":"Rukeyamu","sequence":"additional","affiliation":[{"name":"The First Department of Tuberculosis, The Sixth People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abudureheman","family":"Kaliman","sequence":"additional","affiliation":[{"name":"The First Department of Tuberculosis, The Sixth People\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMsr1512438","article-title":"Twenty years of global surveillance of antituberculosis-drug resistance.","volume":"375","author":"Zignol","year":"2016","journal-title":"N Engl J Med"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"106336","DOI":"10.1016\/j.phrs.2022.106336","article-title":"Bedaquiline and linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: a systematic review and meta-analysis.","volume":"182","author":"Wu","year":"2022","journal-title":"Pharmacol Res"},{"key":"R5-20260514","first-page":"385","article-title":"Advances in the diagnosis and treatment of drug-resistant tuberculosis.","volume":"29","author":"Chu","year":"2021","journal-title":"Chin J Infect Dis"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"110647","DOI":"10.1016\/j.ygeno.2023.110647","article-title":"Sex different effect of antibiotic and probiotic treatment on intestinal microbiota composition in chemically induced liver injury rats.","volume":"115","author":"Fu","year":"2023","journal-title":"Genomics"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1093\/cid\/ciac528","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant ruberculosis.","volume":"76","author":"Padmapriyadarsini","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5588\/ijtldopen.24.0490","article-title":"Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?","volume":"1","author":"Pontali","year":"2024","journal-title":"IJTLD OPEN"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12916-024-03633-3","article-title":"Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin\/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.","volume":"22","author":"Song","year":"2024","journal-title":"BMC Med"},{"key":"R11-20260514","first-page":"868","article-title":"Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.","volume":"11","author":"Marra","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"R12-20260514","first-page":"e02637","article-title":"Oxidative stress and first-line antituberculosis drug-induced hepatotoxicity.","volume":"62","author":"Yew","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/03602532.2023.2215478","article-title":"Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms.","volume":"55","author":"Ezhilarasan","year":"2023","journal-title":"Drug Metab Rev"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"e074866","DOI":"10.1136\/bmj-2023-074866","article-title":"Anti-tuberculosis drug-induced liver injury.","volume":"383","author":"Lim","year":"2023","journal-title":"BMJ"},{"key":"R15-20260514","first-page":"e920350","article-title":"Drug-induced liver injury from anti-tuberculosis treatment: A retrospective cohort study.","volume":"26","author":"Zhao","year":"2020","journal-title":"Med Sci Monit"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/liv.14896","article-title":"Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients.","volume":"41","author":"Jiang","year":"2021","journal-title":"Liver Int"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"19880","DOI":"10.1038\/s41598-023-46565-3","article-title":"Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury.","volume":"13","author":"Akkahadsee","year":"2023","journal-title":"Sci Rep"},{"key":"R18-20260514","first-page":"419","article-title":"Comprehensive analysis of the incidence of adverse reactions to anti-tuberculosis drugs in China.","volume":"30","author":"Xia","year":"2007","journal-title":"Chinese J Tuberc Respir Dis"},{"key":"R19-20260514","doi-asserted-by":"crossref","first-page":"e21836","DOI":"10.1371\/journal.pone.0021836","article-title":"Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.","volume":"6","author":"Shang","year":"2011","journal-title":"PLoS One"},{"key":"R20-20260514","first-page":"2260","article-title":"Skin and lung tuberculosis and anti tuberculosis drug liver injury (ATLI).","volume":"6","author":"Winaya","year":"2015","journal-title":"Int J Sci Res"},{"key":"R22-20260514","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMra1413919","article-title":"Treatment of tuberculosis.","volume":"373","author":"Robert Horsburgh","year":"2015","journal-title":"N Engl J Med"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/trstmh\/tru066","article-title":"Prevalence of extended treatment in pulmonary tuberculosis patients receiving first-line therapy and its association with recurrent tuberculosis in Beijing, China.","volume":"108","author":"Xia","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R24-20260514","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/dmd.121.000389","article-title":"Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug.","volume":"49","author":"Hussain","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"e30955","DOI":"10.1097\/MD.0000000000030955","article-title":"Pyrazinamide related prolonged drug-induced liver injury: a case report.","volume":"101","author":"Wang","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R26-20260514","doi-asserted-by":"crossref","first-page":"934","DOI":"10.5588\/ijtld.12.0782","article-title":"Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre.","volume":"17","author":"Shu","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management.","volume":"3","author":"Ramappa","year":"2013","journal-title":"J Clin Exp Hepatol"},{"key":"R28-20260514","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-017-2330-z","article-title":"Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK.","volume":"17","author":"Abbara","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R29-20260514","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2147\/IDR.S519211","article-title":"Clinical features of anti-tuberculosis drug-induced liver injury and risk factors for severe cases: a retrospective study in China.","volume":"18","author":"Zhang","year":"2025","journal-title":"Infect Drug Resist"},{"key":"R30-20260514","doi-asserted-by":"crossref","first-page":"110439","DOI":"10.1016\/j.cbi.2023.110439","article-title":"Hepatocyte ferroptosis contributes to anti-tuberculosis drug-induced liver injury: involvement of the HIF-1\u03b1\/SLC7A11\/GPx4 axis.","volume":"376","author":"Liu","year":"2023","journal-title":"Chem Biol Interact"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:07:33Z","timestamp":1778756853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":26,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045893","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2025-05-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}